On December 19, 2023 RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, reported the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah (Press release, Renovorx, DEC 19, 2023, View Source [SID1234638701]). The abstract will highlight the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC), a difficult-to-access, solid tumor cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to present research supporting our TAMP therapy platform at the upcoming SIR 2024 conference, the largest professional gathering of interventional radiologists in North America," said Shaun Bagai, CEO of RenovoRx. "This research adds to the continued progress of our pivotal Phase III TIGeR-PaC study in LAPC. We remain steadfast in our commitment to deliver transformative therapies to potentially extend and improve the quality of life of cancer patients."
Presentation Details:
Title: Mesenteric Venous Thrombosis as a Predictor of Target Artery Thrombosis and Tran-Arterial Micro Perfusion Treatment Completion Among Patients with Locally Advanced Pancreatic Cancer
Authors: Michel Accad, MD, et al.
Abstract ID: 1632169
For more information about the conference, visit View Source